Top Banner
FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN THE MANAGEMENT OF POSTERIOR SEGMENT DISORDERS: A REVEALING CASE SERIES OLUFEMI ODERINLO FRCSEd FWACS DRCOphth Consultant Ophthalmologist and Vitreoretina Surgeon EYE FOUNDATION HOSPITAL GROUP
38

OLUFEMI ODERINLO FRCSEd FWACS DRCOphth Consultant Ophthalmologist and Vitreoretina Surgeon

Dec 31, 2015

Download

Documents

fritz-wells

FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN THE MANAGEMENT OF POSTERIOR SEGMENT DISORDERS: A REVEALING CASE SERIES. OLUFEMI ODERINLO FRCSEd FWACS DRCOphth Consultant Ophthalmologist and Vitreoretina Surgeon EYE FOUNDATION HOSPITAL GROUP. INTRODUCTION. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN THE MANAGEMENT OF POSTERIOR

SEGMENT DISORDERS: A REVEALING CASE SERIES

OLUFEMI ODERINLO FRCSEd FWACS DRCOphthConsultant Ophthalmologist and Vitreoretina

Surgeon EYE FOUNDATION HOSPITAL GROUP

Page 2: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

INTRODUCTION

• There are two principles of image acquisition and data processing in OCT:

• Time domain and Fourier domain algorithms.• In time domain OCT, there is a mechanical

moving part that performs the A-scan, and the information along the longitudinal direction is accumulated over the course of the longitudinal scan time. Thus, the rate of the scan is limited by the movement of the part.

Page 3: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• In Fourier domain OCT, the information in an entire A-scan is acquired by a charge-coupled device (CCD) camera simultaneously.

• The A-scan acquisition rate is limited by the CCD camera frame transfer rate and the computer calculation time to perform the Fourier transform of the CCD acquired raw data into A scan information.

• As there is no mechanical movement, the scan time in Fourier domain OCT is faster. This is an important advancement because faster acquisition time means lesser variability in the result due to the patient’s eye movements. This device has a higher resolution than time domain OCT.

Page 4: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

OPTOVUE• The Fourier domain OCT, RTVue

has been approved by the U.S. Food and Drug Administration.

• It takes 26,000 A-scans per second, with a frame rate of 256 to 4,096 A-scans per frame. It has a depth resolution of 5 μm and a transverse resolution of 15 μm.

• The scan range is 2 mm to 2.3 mm in depth and 2 mm to 12 mm in transverse direction. The scan beam wavelength is 840 ± 10 nm, and the exposure power at the pupil is 750 μW.

Page 5: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• Decision making in macula hole

Page 6: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CASE 1

• 36 year old security guard referred for macula hole surgery OD.

• In good general health.• VA 6/12 OD , 6/5 OS• Normal anterior

segments, pupillary reaction and IOP.

• Fundus OS normal

Page 7: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

PSEUDOHOLE

• Idiopathic Serous Retinal Pigment Epithelial Detachment.

• Seen in patients much younger than ARMD definition.

• Few case reports mostly males 20 – 45 years

Page 8: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

Pathophysiology• a non-specific anatomical alteration that may result from any

number of choroidal disorders that disrupt the normal junction between the basement membrane of the RPE and the inner collagenous layer of Bruch’s membrane.

• Idiopathic cases are sometimes associated with ICSC; some believe these two conditions to represent a continuum of a similar underlying pathology.

• Uncomplicated idiopathic serous detachments of the RPE often resolve spontaneously, however, those associated with more generalized damage to the choriocapillaris may be complicated by hemorrhage, choroidal neovascular membrane formation, and disciform scarring.

Page 9: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

MORPHOLOGY: to the fundus photo a hole is a hole

Page 10: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

HOLE MORPHOLOGY

Page 11: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

MEASUREMENTS

(a) base diameter, (b) minimum linear dimension(c) and (d) arms for measuring

hole form factor(e) hole height (f) macular hole inner

opening. Hole form factor ¼ (c+d)/a;

Macular hole index ¼ e/a; Tractional hole index ¼ e/b.

Page 12: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

stage• Modified Gass classification system of macular holes.• Stage• Description• Stage 1a• Yellow spot with loss of foveal depression, no vitreous separation • Stage 1b• Yellow ring with loss of foveal depression, no vitreous separation• Stage 2• Small full-thickness macular hole < 400 microns• Stage 3• Full-thickness macular hole > 400 microns, no vitreous separation• Stage 4• Full-thickness macular hole > 400 microns, complete vitreous separation

Page 14: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• In all patients (100%) with HFF >0.9 the macular hole was closed following one surgical procedure, whereas in eyes with HFF <0.5 anatomical success rate was 67%.

• Better postoperative visual outcome correlated with higher HFF .

Page 15: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

GCC

Page 16: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

Hole closure type

• Closed macular holes are categorised into two patterns based on OCT;

• type 1 closure (closed without foveal neurosensory retinal defect)

• type 2 closure (closed with foveal neurosensory retinal defect).

Page 17: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CASE 2

• 49 year old diabetic with PDR who has had extensive PRP laser.

Page 18: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon
Page 19: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CME/VMT

Page 20: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• Reason for poor vision in heriditary disorders

Page 21: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CASE 3

• 14 year old girl with nyctalopia and difficulty with reading

• Suspicious macula, more of an atrophic picture.

Page 22: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

Fundus

Page 23: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FFA

Page 24: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

Definite CME on FD OCT

Page 25: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FFM

Page 26: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FD OCT

Page 27: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• To evaluate unsatisfactory vision after surgery.

Page 28: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CASE 4

• 41 year old phakic myope with a 5 day history of an inferior retinal detachment OS.

• Round hole at 6 o ‘clock with foveal affectation

Page 29: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• Had scleral buckle with drainage of subretinal fluid.

• Retina reattached• Vision improved from

6/60 to 6/18, significant improvement in CVF

Page 30: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FD OCT

• Non reflective subfoveal cavity representing subfoveal SRF.

Page 31: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

CASE 5

Page 32: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

FD-OCT

Page 33: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

Fd-OCT CLASSIFICATION FOR CNV

• Type 1> 90% sub-RPE.• Type 2 > 90% sub-retinal.• * Minor type 1 component (10% lesion)

visualized.• † Fibrovascular PED.• ‡ Minor type 2 component (10% lesion)

visualized.• Combined• Indeterminate

Page 34: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• showing a mostly subretinal growth pattern of CNVM in an eye with a minimally classic angiographic lesion composition.

• the hyperreflective lesion (cnvm)is outlined in gray with the sub-RPE component of the lesion in a lighter shade.

Page 35: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon
Page 36: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

• WITH FD OCT FOR MACULA LESIONS I CAN SEE CLEARLY NOW.

Page 37: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

THANK YOU

Page 38: OLUFEMI ODERINLO  FRCSEd  FWACS  DRCOphth Consultant Ophthalmologist and  Vitreoretina  Surgeon

REFERENCES

• Desai VN, Hee MR, Puliafito CA. Optical coherence tomography of macular holes. In: Madreperla SA, McCuen BW, eds. Macular hole: pathogenesis, diagnosis and treatment. Oxford: Butterworth-Heinemann 1999:37–47